Capitalization 777.22Cr 739.91Cr 697.86Cr 616.35Cr 1.1TCr 67TCr 1.22TCr 8.31TCr 3.08TCr 28TCr 2.91TCr 2.85TCr 1,18200Cr P/E ratio 2024 *
26.1x
P/E ratio 2025 * 27.1x
Enterprise value 987.87Cr 940.45Cr 886.99Cr 783.4Cr 1.4TCr 86TCr 1.55TCr 11TCr 3.91TCr 36TCr 3.7TCr 3.63TCr 1,50200Cr EV / Sales 2024 *
2.45x
EV / Sales 2025 * 2.41x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.77%
1 week-7.20%
Current month-7.75%
1 month-12.60%
3 months-19.04%
6 months-24.79%
Current year-17.67%
More quotes
1 week
150.79
Extreme 150.79
164.32
1 month
150.79
Extreme 150.79
171.75
Current year
150.79
Extreme 150.79
193.56
1 year
150.79
Extreme 150.79
275.00
3 years
150.79
Extreme 150.79
308.15
5 years
95.58
Extreme 95.58
460.21
10 years
59.99
Extreme 59.99
460.21
More quotes
Director TitleAgeSince
Chief Executive Officer 74 01/01/1992
Director of Finance/CFO 52 01/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2014
Manager TitleAgeSince
Director/Board Member 77 01/01/2003
Chairman 74 01/01/2000
Director/Board Member 68 29/10/2008
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-0.77%-7.20%-38.06%-51.38% 777.22Cr
-0.43%-1.39%+28.71%-1.26% 4.79TCr
-1.33%-7.06%-19.89%-15.40% 3.41TCr
-0.45%-1.71%-0.38%+22.57% 2.66TCr
+0.04%+6.58%+72.73%+81.40% 1.65TCr
+1.95%-3.75%-35.82%-23.17% 1.54TCr
+6.79%+29.70% - - 1.41TCr
+3.35%+1.20%-63.80%-78.17% 1.27TCr
-1.12%-9.44%-7.47%-36.10% 1.04TCr
-0.65%-3.93%-13.74%+144.96% 1.04TCr
Average +0.74%+0.38%-8.64%+4.83% 1.96TCr
Weighted average by Cap. +0.34%-0.22%+0.08%+4.08%
See all sector performances

Financials

2024 *2025 *
Net sales 403.11Cr 383.76Cr 361.94Cr 319.67Cr 571.12Cr 35TCr 633.76Cr 4.31TCr 1.6TCr 15TCr 1.51TCr 1.48TCr 61TCr 390.55Cr 371.81Cr 350.67Cr 309.72Cr 553.34Cr 34TCr 614.03Cr 4.18TCr 1.55TCr 14TCr 1.46TCr 1.43TCr 59TCr
Net income 30Cr 29Cr 27Cr 24Cr 43Cr 2.61TCr 47Cr 322.02Cr 119.3Cr 1.09TCr 112.91Cr 110.64Cr 4.58TCr 29Cr 27Cr 26Cr 23Cr 40Cr 2.47TCr 45Cr 304.74Cr 112.9Cr 1.03TCr 106.85Cr 104.7Cr 4.33TCr
Net Debt 210.65Cr 200.54Cr 189.14Cr 167.05Cr 298.45Cr 18TCr 331.18Cr 2.25TCr 834.33Cr 7.63TCr 789.65Cr 773.75Cr 32TCr 165.6Cr 157.65Cr 148.69Cr 131.32Cr 234.62Cr 14TCr 260.35Cr 1.77TCr 655.89Cr 6TCr 620.77Cr 608.27Cr 25TCr
More financial data * Estimated data
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Employees
21,100
Calendar
More about the company
Date Price Change Volume
14/25/14 151.99 $ -0.77% 841,132
13/25/13 153.17 $ -0.54% 901,107
12/25/12 154.00 $ -0.58% 1,278,385
11/25/11 154.90 $ -3.12% 946,154
10/25/10 159.89 $ -2.38% 1,709,860

Delayed Quote Nyse, February 15, 2025 at 02:30 am IST

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
151.99USD
Average target price
189.23USD
Spread / Average Target
+24.50%
Consensus

Quarterly revenue - Rate of surprise